Get ready to revolutionize ADHD treatment with a groundbreaking acquisition! The future of ADHD care is here, and it's all about precision and objectivity.
HarmonEyes, the AI-powered eye-tracking pioneer, has just acquired iFocus Health, a game-changer in ADHD medication management. This move adds a powerful tool to HarmonEyes' human performance platform, offering a unique, real-time insight into how ADHD treatments work.
But here's where it gets controversial... Traditionally, ADHD treatment has relied on subjective methods like self-reports and behavioral checklists. iFocus Health, however, has developed a clinically validated solution that tracks eye movement, providing objective data on how patients respond to medication. This shift from guesswork to precision is a game-changer, making ADHD treatment more personalized and effective.
Adi Diner, CEO of iFocus Health, puts it perfectly: "ADHD isn't just about distraction; it's about underperformance in a world that demands focus. With HarmonEyes, we're taking a giant leap forward, offering a technology that measures treatment efficacy in real time."
Now rebranded as HarmonEyes Focus, this technology is a key part of HarmonEyes' mission to understand human performance through eye movement. HarmonEyes' AI models already deliver real-time insights into cognitive states, and with iFocus, they can now measure and improve ADHD treatment responses. Whether in healthcare, education, or daily life, the goal is to help people perform at their best.
And this is the part most people miss... According to the CDC, millions of children and adults in the U.S. are diagnosed with ADHD, yet the tools for assessing treatment efficacy have been stagnant for decades. HarmonEyes Focus changes this, offering clinicians a data-driven view of medication effectiveness, and thus, a more confident and precise approach to treatment.
Adam Gross, CEO of HarmonEyes, emphasizes the strategic importance of this acquisition: "We're building a foundational model for eye-tracking to understand the human state. iFocus brings a proven use case that fits perfectly within our vision. By combining their approach with our real-time eye-tracking AI, we're unlocking new ways to support focus and mental performance."
The acquisition of iFocus by HarmonEyes opens up exciting opportunities to bring objectivity to human decision-making. In the future, this platform could support neurodivergent conditions, optimize performance in classrooms and workplaces, and even improve focus in clinical settings. The possibilities are endless!
For more information on HarmonEyes and its cutting-edge eye-tracking solutions, visit www.harmoneyes.com. Get ready to witness the power of AI-driven eye-tracking in action!
